NetworkNewsBreaks – Atossa Genetics, Inc. (NASDAQ: ATOS) Opens Enrollment in Study of Endoxifen; Shares Down
Shares of Atossa Genetics (NASDAQ: ATOS) are 10% lower after the company this morning said that it has opened enrollment of a phase 1 study of endoxifen. Endoxifen is an active metabolite of tamoxifen, an FDA-approved drug for breast cancer. The phase 1 study is a placebo-controlled, repeat dose study of 48 healthy female volunteers. The objective is to assess the pharmacokinetics of proprietary formulations of both oral and topical endoxifen dosage forms over 28 days, as well as to assess safety and tolerability. To view the full press release, visit: http://nnw.fm/1Z9Fg About Atossa Genetics Atossa Genetics Inc., is a…